

Patients' and consumers' organisation funding sources

NAME OF ORGANISATION: Myeloma Patients Europe aisbl (MPE)

YEAR: 2023

MPE Industry ¹ related income ²		
Name of company/ funder	Amount of income	% of overall organisation's income
AbbVie	2.500 €	0,2%
Alexion	20.000 €	1,7%
Amgen	15.000 €	1,2%
BeiGene	31.402 €	2,6%
Bristol Myers Squibb	155.000 €	12,9%
Daiichi	1.234 €	0,1%
GlaxoSmithKline	66.253 €	5,5%
Janssen	178.681 €	14,8%
Novartis	30.000 €	2,5%
Oncopeptides	4.840 €	0,4%
Pfizer	210.015 €	17,4%
Prothena	17.500 €	1,5%
Regeneron	98.000 €	8,1%

¹ Industry is defined as commercial manufacturers of healthcare products and services, including distributors and wholesalers, etc.

² This should reflect the overall funding received from industry, including, e.g. projects, conferences, etc.

Roche	53.700 €	4,5%
Sandoz	6.284 €	0,5%
Sanofi	88.730 €	7,4%
Sebia	800 €	0,1%
SkylineDX	1.000 €	0,1%
Menarini Stemline	66.150 €	5,5%
Takeda	87.280 €	7,2%
Subtotal:	1.134.369 €	94,1%

MPE Non-industry related income – Public Funding		
Source of funding ³	Amount of income	% of overall organisation's income
H2020 CARAMBA	17.377 €	1,4%
HE ASCERTAIN	16.303 €	1,4%
IMI HARMONY	411 €	0,0%
IMI SISAQoL	21.696 €	1,8%
T2Evolve	1.000 €	0,1%
Subtotal:	56.754 €	4,7%

³ E.g. membership fees, donations.

MPE Non-industry related income		
EPAI gUG	2.703 €	0,2%
ESMO	3.832 €	0,3%
Kings College London	2.000 €	0,2%
MJH Life Sciences	2.299 €	0,2%
OHE	1.250 €	0,1%
Patvocates	828 €	0,1%
Other Non-Industry (various)	1.147 €	0,1%
Refund - Non-Industry	302 €	0,0%
Subtotal:	14.360 €	1,2%
TOTAL⁴:	1.205.483 €	100,0%

Information required to be included on organisation's website	Please include links below:
Funding sources:	https://www.mpeurope.org/about-mpe/funding-sources/
Overall proportion of industry and non-industry:	Industry: 94,1%; Non-Industry incl. Public Funding: 5,9%
Percentage of the highest contribution from a single company:	17,4% of overall organizations income

⁴ In case the total figures in this table do not match those in the financial statement, please provide justification (attached here or as an email).

Comments/explanatory notes:

When completing the form you may refer to the guidance document here (in particular point 4, pages 8-9):

http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2015/05/WC500187018.pdf